Long-Term Follow-Up of Lower Dose Dasatinib (50 Mg Daily) as Frontline Therapy in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Cancer - United States
doi 10.1002/cncr.32504

Related search